This Mid-Cap Split: Why Copart Looks Misread, While GE HealthCare and Equitable Hold More Risk

Copart looks more attractive than GE HealthCare or Equitable this week

Among these mid-cap names, the market may be rewarding the simpler story rather than the stronger one. Using the available evidence, Copart looks the most misread, GE HealthCare sits in the middle, and Equitable carries the most near-term risk for fresh buyers.

My ranking is: 1) Copart (CPRT), 2) GE HealthCare (GEHC), 3) Equitable (EQH).

Copart gets the top spot because a weak headline quarter appears to be overshadowing a sturdier cash-generation profile. The latest report showed revenue down 3.6% and net income down 9.5%, but free cash flow rose 58%, cash reached $5.1 billion, and the company had no debt. That kind of disconnect can create opportunity if the underlying business remains intact.

GEHC ranks second because the evidence points in conflicting directions. Bears can cite organic revenue disappointing over the past two years and Wall Street's implied 4.5% growth over the next year. Bulls can point to record orders and backlog in the latest quarter. That debate creates uncertainty more than a clear buying signal.

Equitable lands last. It did report solid first quarter results and announced an all-stock merger with Corebridge Financial. But it also disclosed $7.1 billion of Asset Management outflows, which makes the setup less compelling than the headline catalyst suggests.

Copart's weak quarter looks temporary, not structural

The quarter ended January 31, 2026 and was reported on February 19, 2026. The headline numbers were soft, which invites investors to label the business cyclical. But the deeper signal is more constructive: free cash flow rose 58%, while the company held $5.1 billion in cash and equivalents with no debt.

What the market may be misreading

The bear case is straightforward: revenue fell 3.6% and net income fell 9.5%. That is enough to trigger a sell-the-news reaction.

The stronger evidence, however, points to a temporary pressure point rather than a broken model. The total number of insured vehicles in the U.S. dropped by 10.7%, which could weigh on volume without indicating that Copart's platform weakened. At the same time, total loss frequency was 23.1% in 2025 after 15.6% in 2015, and Copart expects the total loss frequency to keep rising in the foreseeable future. That backdrop still supports the long-term setup.

What to watch next

The next report matters because investors are likely to look for confirmation either way. Key things to watch:

• Whether revenue and net income recover after the quarter ended January 31, 2026
• Whether free cash flow rose 58% holds up or improves
• Whether the total number of insured vehicles in the U.S. dropped by 10.7% starts to normalize
• Whether Copart expects the total loss frequency to keep rising in the foreseeable future continues to translate into business momentum

What would weaken the thesis

This view would need to change if weakness broadens beyond one quarter. A second soft report, weaker cash flow, or signs that the insured-vehicle drop is persisting would make the slowdown look more structural than the market currently assumes.

Why GEHC and Equitable still look less attractive

GE HealthCare has a legitimate positive counterpoint in record orders and backlog, but that does not fully resolve the concern that organic revenue disappointing over the past two years reflects a slower core demand backdrop. Until those signals start moving in the same direction, the story looks more conflicted than compelling.

Equitable is not weak on every front. The company reported solid first quarter results and announced an all-stock merger with Corebridge Financial. But it also faced net outflows of $7.1 billion in Asset Management, which keeps the risk-reward less attractive than Copart's for fresh capital this week.